logo-loader

Theralase approved to sell next-gen laser in United States

Last updated: 08:37 25 Nov 2015 EST, First published: 03:37 25 Nov 2015 EST

kneepain
It represent the first of four strategic objectives Theralase is targeting

Theralase Technologies (OTCMKTS:TLTFF, CVE:TLT) has received approval from the US Food & Drugs Administration (FDA) for its next generation therapeutic laser system.

The company’s new TLC-2000 system, to provide temporary relief of pain from knee disorders,  can now immediately be marketed in the United States as a result.

Roger Dumoulin-White, Theralase chief executive, says the approval represent the first of four major strategic objectives currently pursued by company by year end.

The other objectives are to secure approval for TLC-2000 in Canada, review ethics board approval for a Phase 1b trial for its anti-cancer technology to treat Non-Muscle Invasive Bladder Cancer (NMIBC), and Health Canada approval to start the NMIBC trial.

Theralase Technologies shares update on Phase II Bladder Cancer study

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive Bladder Cancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from...

on 01/16/2024